Search

Your search keyword '"Kallel, Amani"' showing total 232 results
Start Over Author "Kallel, Amani"
232 results on '"Kallel, Amani"'

1. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

Author

Acosta, Julio, Al-Khnifsawi, Mutaz, Alnouri, Fahad, Amar, Fahma, Atanasov, Atanas G., Bajraktari, Gani, Banach, Maciej, Gouni-Berthold, Ioanna, Bhaskar, Sonu, Bielecka-Dąbrowa, Agata, Bjelakovic, Bojko, Bruckert, Eric, Bytyçi, Ibadete, Cafferata, Alberto, Ceska, Richard, Cicero, Arrigo F.G., Chlebus, Krzysztof, Collet, Xavier, Daccord, Magdalena, Descamps, Olivier, Djuric, Dragan, Durst, Ronen, Ezhov, Marat V., Fras, Zlatko, Gaita, Dan, Hernandez, Adrian V., Jones, Steven R., Jozwiak, Jacek, Kakauridze, Nona, Kallel, Amani, Katsiki, Niki, Khera, Amit, Kostner, Karam, Kubilius, Raimondas, Latkovskis, Gustavs, John Mancini, G.B., David Marais, A., Martin, Seth S., Martinez, Julio Acosta, Mazidi, Mohsen, Mikhailidis, Dimitri P., Mirrakhimov, Erkin, Miserez, Andre R., Mitchenko, Olena, Mitkovskaya, Natalya P., Moriarty, Patrick M., Mohammad Nabavi, Seyed, Nair, Devaki, Panagiotakos, Demosthenes B., Paragh, György, Pella, Daniel, Penson, Peter E., Petrulioniene, Zaneta, Pirro, Matteo, Postadzhiyan, Arman, Puri, Raman, Reda, Ashraf, Reiner, Željko, Radenkovic, Dina, Rakowski, Michał, Riadh, Jemaa, Richter, Dimitri, Rizzo, Manfredi, Ruscica, Massimiliano, Sahebkar, Amirhossein, Serban, Maria-Corina, Shehab, Abdullah M.A, Shek, Aleksandr B., Sirtori, Cesare R., Stefanutti, Claudia, Tomasik, Tomasz, Toth, Peter P., Viigimaa, Margus, Valdivielso, Pedro, Vinereanu, Dragos, Vohnout, Branislav, von Haehling, Stephan, Vrablik, Michal, Wong, Nathan D., Yeh, Hung-I, Zhisheng, Jiang, Zirlik, Andreas, Colletti, Alessandro, Mancini, John, Marais, David, Moriarty, Patrick, and Cicero, Arrigo Francesco Giuseppe

Published
2023
Full Text
View/download PDF

3. Plasma levels of obestatin and ghrelin and obestatin/ghrelin ratio in obese patients

Author

Sfar, Myriam, Jemaa, Houda Ben, Kallel, Amani, Ben-Mahrez, Kamel, Feki, Moncef, and Slama, Fethi Ben

Subjects
Obesity, Ghrelin, Obestatin, BMI and Lipid Parameters, digestive, oral, and skin physiology, hormones, hormone substitutes, and hormone antagonists
Abstract

Background:Obestatin and ghrelin are two gastric hormones that have a potential role in dietary intake regulation. Obestatin/ghrelin ratio has been proposed as activity markers in obesity. The study aimed to evaluate ghrelin, obestatin and the ghrelin/obestatin ratio in obese compared to control subjects and to determine their relationship with anthropometric and metabolic parameters. Methods: Fasting obestatin and ghrelin levels were measured using enzyme-linked immunosorbent assay ELISA in 28 obese and 24 healthy subjects. The fasting ghrelin/obestatin ratio was calculated. Anthropometric and metabolic parameters were also assessed. Results: Obese patients had significantly lower obestatin and ghrelin blood levels compared with controls. The Ghrelin/Obestatin ratio was significantly lower in obese group 0.813±0.0417 ng/ml than in the control group 0.896±0.049 ng/ml, (p Conclusion: Circulating preprandial ghrelin to obestatin ratio is decreased obese subjects. We suggest that low preprandial ghrelin to obestatin ratio may be involved in the etiology and pathophysiology of obesity.

Published
2022

4. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

Author

Rizzo, Manfredi, primary, Colletti, Alessandro, additional, Penson, Peter E., additional, Katsiki, Niki, additional, Mikhailidis, Dimitri P., additional, Toth, Peter P., additional, Gouni-Berthold, Ioanna, additional, Mancini, John, additional, Marais, David, additional, Moriarty, Patrick, additional, Ruscica, Massimiliano, additional, Sahebkar, Amirhossein, additional, Vinereanu, Dragos, additional, Cicero, Arrigo Francesco Giuseppe, additional, Banach, Maciej, additional, Acosta, Julio, additional, Al-Khnifsawi, Mutaz, additional, Alnouri, Fahad, additional, Amar, Fahma, additional, Atanasov, Atanas G., additional, Bajraktari, Gani, additional, Bhaskar, Sonu, additional, Bielecka-Dąbrowa, Agata, additional, Bjelakovic, Bojko, additional, Bruckert, Eric, additional, Bytyçi, Ibadete, additional, Cafferata, Alberto, additional, Ceska, Richard, additional, Cicero, Arrigo F.G., additional, Chlebus, Krzysztof, additional, Collet, Xavier, additional, Daccord, Magdalena, additional, Descamps, Olivier, additional, Djuric, Dragan, additional, Durst, Ronen, additional, Ezhov, Marat V., additional, Fras, Zlatko, additional, Gaita, Dan, additional, Hernandez, Adrian V., additional, Jones, Steven R., additional, Jozwiak, Jacek, additional, Kakauridze, Nona, additional, Kallel, Amani, additional, Khera, Amit, additional, Kostner, Karam, additional, Kubilius, Raimondas, additional, Latkovskis, Gustavs, additional, John Mancini, G.B., additional, David Marais, A., additional, Martin, Seth S., additional, Martinez, Julio Acosta, additional, Mazidi, Mohsen, additional, Mirrakhimov, Erkin, additional, Miserez, Andre R., additional, Mitchenko, Olena, additional, Mitkovskaya, Natalya P., additional, Moriarty, Patrick M., additional, Mohammad Nabavi, Seyed, additional, Nair, Devaki, additional, Panagiotakos, Demosthenes B., additional, Paragh, György, additional, Pella, Daniel, additional, Petrulioniene, Zaneta, additional, Pirro, Matteo, additional, Postadzhiyan, Arman, additional, Puri, Raman, additional, Reda, Ashraf, additional, Reiner, Željko, additional, Radenkovic, Dina, additional, Rakowski, Michał, additional, Riadh, Jemaa, additional, Richter, Dimitri, additional, Rizzo, Manfredi, additional, Serban, Maria-Corina, additional, Shehab, Abdullah M.A, additional, Shek, Aleksandr B., additional, Sirtori, Cesare R., additional, Stefanutti, Claudia, additional, Tomasik, Tomasz, additional, Viigimaa, Margus, additional, Valdivielso, Pedro, additional, Vohnout, Branislav, additional, von Haehling, Stephan, additional, Vrablik, Michal, additional, Wong, Nathan D., additional, Yeh, Hung-I, additional, Zhisheng, Jiang, additional, and Zirlik, Andreas, additional

Published
2023
Full Text
View/download PDF

5. The role of nutraceuticals in heart failure muscle wasting as a result of inflammatory activity. The International Lipid Expert Panel (ILEP) Position Paper.

Author

Bielecka-Dabrowa, Agata, Banach, Maciej, Wittczak, Andrzej, Cicero, Arrigo F. G., Kallel, Amani, Kubilius, Raimondas, Mikhailidis, Dimitri P., Sahebkar, Amirhossein, Stoian, Anca Pantea, Vinereanu, Dragos, Penson, Peter E., and von Haehling, Stephan

Subjects
MYOCARDIUM, HEART failure, HEART failure patients, FUNCTIONAL foods, SKELETAL muscle, LEGAL evidence
Abstract

Muscle wasting is one of the main causes for exercise intolerance and ventilatory inefficiency in patients with heart failure and a strong predictor of frailty and reduced survival. The prevalence of sarcopenia is at least 20% in patients with heart failure. Patients with heart failure often have subclinical systemic inflammation, which may exert sustained effects on skeletal muscle. Besides exercise, nutrition should also be carefully evaluated as an appropriate diet with selected nutraceuticals may be able to stimulate muscle anabolism and inhibit muscle catabolism. This review summarizes the epidemiological and clinical trial evidence supporting the recommendations for the use of nutraceuticals with anti-inflammatory properties in heart failure and provides an overview of the state of the evidence for nutraceutical supplementation to prevent and/or mitigate heart failure muscle wasting. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP)

Author

Ruscica, Massimiliano, primary, Penson, Peter E., additional, Ferri, Nicola, additional, Sirtori, Cesare R., additional, Pirro, Matteo, additional, Mancini, G.B. John, additional, Sattar, Naveed, additional, Toth, Peter P., additional, Sahebkar, Amirhossein, additional, Lavie, Carl J., additional, Wong, Nathan D., additional, Banach, Maciej, additional, Acosta, Julio, additional, Al-Khnifsawi, Mutaz, additional, Alnouri, Fahad, additional, Amar, Fahma, additional, Atanasov, Atanas G., additional, Bajraktari, Gani, additional, Bhaskar, Sonu, additional, Bjelakovic, Bojko, additional, Bruckert, Eric, additional, Ceska, Richard, additional, Cicero, Arrigo F.G., additional, Collet, Xavier, additional, Descamps, Olivier, additional, Djuric, Dragan, additional, Durst, Ronen, additional, Ezhov, Marat V., additional, Fras, Zlatko, additional, Gaita, Dan, additional, Hernandez, Adrian V., additional, Jones, Steven R., additional, Jozwiak, Jacek, additional, Kakauridze, Nona, additional, Kallel, Amani, additional, Katsiki, Niki, additional, Khera, Amit, additional, Kostner, Karam, additional, Kubilius, Raimondas, additional, Latkovskis, Gustavs, additional, Marais, A. David, additional, Martin, Seth S., additional, Martinez, Julio Acosta, additional, Mazidi, Mohsen, additional, Mikhailidis, Dimitri P., additional, Mirrakhimov, Erkin, additional, Miserez, Andre R., additional, Mitchenko, Olena, additional, Mitkovskaya, Natalya P., additional, Moriarty, Patrick M., additional, Nabavi, Seyed Mohammad, additional, Nair, Devaki, additional, Panagiotakos, Demosthenes B., additional, Paragh, György, additional, Pella, Daniel, additional, Petrulioniene, Zaneta, additional, Postadzhiyan, Arman, additional, Puri, Raman, additional, Reda, Ashraf, additional, Reiner, Željko, additional, Radenkovic, Dina, additional, Rakowski, Michał, additional, Riadh, Jemaa, additional, Richter, Dimitri, additional, Rizzo, Manfredi, additional, Ruscica, Massimiliano, additional, Serban, Maria-Corina, additional, Shehab, Abdulla M.A., additional, Shek, Aleksandr B., additional, Stefanutti, Claudia, additional, Tomasik, Tomasz, additional, Viigimaa, Margus, additional, Valdivielso, Pedro, additional, Vinereanu, Dragos, additional, Vohnout, Branislav, additional, von Haehling, Stephan, additional, Vrablik, Michal, additional, Yeh, Hung-I, additional, Zhisheng, Jiang, additional, and Zirlik, Andreas, additional

Published
2021
Full Text
View/download PDF

24. Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel(ILEP)

Author

Penson, Peter E., Bruckert, Eric, Marais, David, Reiner, Željko, Pirro, Matteo, Sahebkar, Amirhossein, Bajraktari, Gani, Mirrakhimov, Erkin, Rizzo, Manfredi, Mikhailidis, Dimitri P., Sachinidis, Alexandros, Gaita, Dan, Latkovskis, Gustavs, Mazidi, Mohsen, Toth, Peter P., Pella, Daniel, Alnouri, Fahad, Postadzhiyan, Arman, Yeh, Hung‐I, Mancini, G.B. John, Haehling, Stephan, Banach, Maciej, Acosta, Julio, Al‐Khnifsawi, Mutaz, Alnouri, Fahad, Amar, Fahma, Atanasov, Atanas G., Bajraktari, Gani, Banach, Maciej, Bhaskar, Sonu, Bytyçi, Ibadete, Bjelakovic, Bojko, Bruckert, Eric, Cafferata, Alberto, Ceska, Richard, Cicero, Arrigo F.G., Collet, Xavier, Daccord, Magdalena, Descamps, Olivier, Djuric, Dragan, Durst, Ronen, Ezhov, Marat V., Fras, Zlatko, Gaita, Dan, Hernandez, Adrian V., Jones, Steven R., Jozwiak, Jacek, Kakauridze, Nona, Kallel, Amani, Katsiki, Niki, Khera, Amit, Kostner, Karam, Kubilius, Raimondas, Latkovskis, Gustavs, Mancini, G.B. John, Marais, A. David, Martin, Seth S., Martinez, Julio Acosta, Mazidi, Mohsen, Mikhailidis, Dimitri P., Mirrakhimov, Erkin, Miserez, Andre R., Mitchenko, Olena, Mitkovskaya, Natalya P., Moriarty, Patrick M., Nabavi, Seyed Mohammad, Nair, Devaki, Panagiotakos, Demosthenes B., Paragh, György, Pella, Daniel, Penson, Peter E., Petrulioniene, Zaneta, Pirro, Matteo, Postadzhiyan, Arman, Puri, Raman, Reda, Ashraf, Reiner, Željko, Radenkovic, Dina, Rakowski, Michał, Riadh, Jemaa, Richter, Dimitri, Rizzo, Manfredi, Ruscica, Massimiliano, Sahebkar, Amirhossein, Sattar, Naveed, Serban, Maria‐Corina, Shehab, Abdullah M.A., Shek, Aleksandr B., Sirtori, Cesare R., Stefanutti, Claudia, Tomasik, Tomasz, Toth, Peter P., Viigimaa, Margus, Valdivielso, Pedro, Vinereanu, Dragos, Vohnout, Branislav, Haehling, Stephan, Vrablik, Michal, Wong, Nathan D., Yeh, Hung‐I, Zhisheng, Jiang, and Zirlik, Andreas

Abstract

Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin‐associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3–5%). Many perceived AEs are misattributed (e.g. physical musculoskeletal injury and inflammatory myopathies), and subjective symptoms occur as a result of the fact that patients expect them to do so when taking medicines (the nocebo/drucebo effect)—what might be truth even for over 50% of all patients with muscle weakness/pain. Clear guidance is necessary to enable the optimal management of plasma in real‐world clinical practice in patients who experience subjective AEs. In this Position Paper of the International Lipid Expert Panel (ILEP), we present a step‐by‐step patient‐centred approach to the identification and management of SAMS with a particular focus on strategies to prevent and manage the nocebo/drucebo effect and to improve long‐term compliance with lipid‐lowering therapy.

Published
2022
Full Text
View/download PDF

29. Association of MTHFR C677T, MTHFR A1298C, and MTRR A66G Polymorphisms with Neural Tube Defects in Tunisian Parents

Author

Nasri, Kaouther, primary, Midani, Fatma, additional, Kallel, Amani, additional, Ben Jemaa, Nadia, additional, Aloui, Mariem, additional, Boulares, Miryam, additional, Lassoued, Mehdi, additional, Ben Halima, Meriam, additional, Ben Wafi, Safa, additional, Soussi, Mariem, additional, Mahjoubi, Imen, additional, Baara, Abir, additional, Ben Fradj, Mohamed Kacem, additional, Omar, Souhail, additional, Feki, Moncef, additional, Jemaa, Riadh, additional, Gaigi, Soumeya Siala, additional, and Marrakchi, Raja, additional

Published
2019
Full Text
View/download PDF

30. Low Plasma 25-Hydoxyvitamin D at Diagnosis Predicts Poor Outcomes in Patients with Bladder Cancer: A Prospective Cohort Study.

Author

Ben Fradj, Mohamed Kacem, Bibi, Mokhtar, Hammami, Mohamed Bassem, Kallel, Amani, Nouira, Yassine, and Feki, Moncef

Subjects
APPLICATION software, BLADDER tumors, CANCER patients, CANCER relapse, CONFIDENCE intervals, PATIENT aftercare, IMMUNOASSAY, LONGITUDINAL method, HEALTH outcome assessment, VITAMIN D, VITAMIN D deficiency, WORLD Wide Web, PROPORTIONAL hazards models, DISEASE progression, DESCRIPTIVE statistics
Abstract

This study aimed to investigate whether plasma 25-hydroxyvitamin D (25-OHD) at diagnosis predicts poor outcomes in patients with urothelial bladder cancer. A total of 177 patients with non-muscle-invasive bladder cancer (NMIBC) were prospectively followed up over a period extending beyond 6 years. Data on poor outcomes (ie., recurrence, progression, and mortality) were collected. Plasma 25-OHD was measured by immunoassay. Cutoff-Finder web application was used to determine the best 25-OHD cutoff point to predict a specific poor outcome. Cox-hazard models were applied to test how plasma 25-OHD affect patients outcome while adjusting for potential confounding factors. During the follow-up period, tumor recurrence and progression occurred in 40.7% and 14.1% of patients, respectively and 11.3% of patients died. Baseline 25-OHD was lower in patients who experienced poor outcome (12.2 ± 7.44 vs. 16.7 ± 10.6 ng/mL; p < 0.001). Multi-adjusted HR (95% CI) for vitamin D deficiency (25-OHD < 12 ng/mL) was 2.09 (1.27-3.44) for recurrence, 2.63 (1.06-6.49) for progression and 2.93 (1.04-8.25) for mortality in patients with NMIBC. Low plasma 25-OHD in NMIBC patients is associated with higher risk of poor outcome. Future work is required to test whether correction of vitamin D deficiency will improve quality of life and extend survival in these patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

34. The Role of Genetic Variants (rs869109213 and rs2070744) Of the Gene and II in the α2 Subunit of the α2β1 Integrin Gene in Diabetic Retinopathy in a Tunisian Population.

Author

Midani, Fatma, Ben Amor, Zohra, El Afrit, Mohamed Ali, Kallel, Amani, Feki, Moncef, and Soualmia, Hayet

Subjects
NITRIC-oxide synthases, DIABETIC retinopathy, TUNISIANS, INTEGRINS, GENETIC polymorphisms
Abstract

Purpose: In this study, we investigated the association of two polymorphisms (rs869109213 and rs2070744) in the eNOS gene and one polymorphism BglII in the α2β1 integrin gene (ITGA2) with the risk of diabetic retinopathy (DR) in a Tunisian population. Methods: The study investigated of 110 type 2 diabetes mellitus (T2DM) and 127 DR patients. The genotypes of the eNOS 4b/4a (rs869109213) and -786T/C (rs2070744) polymorphisms and of the BglII polymorphism of ITGA2 were studied using the PCR or PCR-RFLP method. Results: The genotype distributions of the two polymorphisms in eNOS 4b4a and eNOS (-786T/C) were significantly different between T2DM and DR patients (p < .004 and p = .033, respectively). These polymorphisms were associated with the risk of DR (OR = 2.65, 95%CI [1.45-4.84], p = .002) for the eNOS 4b4a genotype and (OR = 2.43, 95%CI [1.06 - 5.56], p = .036) for the CC genotype of the eNOS gene (-786T/C). Similarly, the genotype distribution of the BglII polymorphism was significantly different between the two groups studied (p = .037). This polymorphism was associated with an increased risk of DR (OR = 4.03, 95% CI [1.17 - 7.85], p = .022) for BglII(+/+). Conclusion: The present study suggests that the polymorphisms 4b4a and -786T/C in the eNOS gene might be associated with DR. In addition, the BglII polymorphism in the ITGA2 gene was a risk factor for DR. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

35. Association between paraoxonase-1 gene promoter -108C/T polymorphism and myocardial infarction in the Tunisian male population / Tunuslu erkek populasyonunda miyokard enfarktüs ile paraoksonaz -1 gen başlatıcı -108C/T polimorfizmi arasındaki ilişki

Author

Sbai, Mohamed Hédi, primary, Kallel, Amani, additional, Sediri, Yousra, additional, Lassoued, Mehdi, additional, Feki, Moncef, additional, Mourali, Mohamed Sami, additional, Kaabachi, Naziha, additional, and Jemaa, Riadh, additional

Published
2016
Full Text
View/download PDF

37. 0185: Prevalence of conventional risk factors in 44154 Tunisians patients with coronary heart disease

Author

Jemaa, Riadh, primary, Kallel, Amani, additional, Sbaï, Mohamed Hédi, additional, Rabie, Razgallah, additional, Kafsi, Mohamed Naceur, additional, Zaouali, R.M, additional, Mechmeche, Rachid, additional, Haouala, Habib, additional, Slimane, M.L, additional, Belhani, A., additional, Ben Khalfallah, A., additional, Gamra, H., additional, Maatouk, F., additional, Ammar, H., additional, Chaouech, A., additional, Boughzala, E., additional, Bouajina, A., additional, and Chehaibi, N., additional

Published
2016
Full Text
View/download PDF

42. Association of FokI polymorphism of vitamin D receptor with urothelial bladder cancer in Tunisians: role of tobacco smoking and plasma vitamin D concentration

Author

Ben Fradj, Mohamed Kacem, primary, Kallel, Amani, additional, Gargouri, Mohamed Mourad, additional, Chehida, Mohamed Ali Ben, additional, Sallemi, Ahmed, additional, Ouanes, Yassine, additional, Rhouma, Sami Ben, additional, Riadh, Jemaa, additional, Feki, Moncef, additional, Nouira, Yassine, additional, and Kaabachi, Naziha, additional

Published
2015
Full Text
View/download PDF

47. Angiotensin II Receptor Gene A1166C Variant and Hypertension in Tunisian Population

Author

Soualmia, Hayet, Ayadi, Ilhem, Kallel, Amani, Jemaa, Riadh, Feki, Moncef, Sanhaji, Haifa, Kaabachi, Naziha, Soualmia, Hayet, Ayadi, Ilhem, Kallel, Amani, Jemaa, Riadh, Feki, Moncef, Sanhaji, Haifa, and Kaabachi, Naziha

Abstract

Many genes have been proposed as candidate genes for hypertension. Among these genes, the angiotensin II type 1 receptor gene (AGTR1) has been investigated in the pathogenesis of hypertension, but studies have often generated controversial results. In this study, we analyzed the relationship between the A1166C variant of the AGTR1 and hypertension in a sample from the Tunisian population. Analysis of the AGTR1 genotypes was performed in 388 Tunisian patients with hypertension and 428 healthy subjects by polymerase chain reaction-restriction fragment length polymorphism. The results shows that the AGTR1 genotypes distribution and allele frequencies were not significantly different between the hypertensive and normotensive subjects (p>0.05). This polymorphism was not associated with hypertension (OR = 1.03, 95% CI [0.47-2.24]; p = 0.58) for AC and (OR = 1.19, 95% CI [0.65-2.19]; p = 0.83) for CC in comparison to the AA wild homozygous. After adjustment for the confounding factors of age, gender, body mass index, fasting glucose concentration, dyslipidemia and smoking, the OR for hypertension remained no significant (OR = 1.28, 95% CI [0.87-1.84]; p = 0.50) for CC vs AA. Furthermore, no relationship was found between clinical characteristics and AGTR1 genotypes. In the conclusion; our data suggested that the A1166C variant of the AGTR1 is not involved in the pathogenesis of hypertension in the Tunisian population.

Published
2014

48. ScaI Atrial Natriuretic Peptide Gene Polymorphism and Hypertension in the Tunisian Population

Author

Soualmia, Hayet, Ayadi, Ilhem, Kallel, Amani, Midani, Fatma, Jemaa, Riadh, Feki, Moncef, Sanhaji, Haifa, Kaabachi, Naziha, Soualmia, Hayet, Ayadi, Ilhem, Kallel, Amani, Midani, Fatma, Jemaa, Riadh, Feki, Moncef, Sanhaji, Haifa, and Kaabachi, Naziha

Abstract

Numerous genetic variants have been linked to hypertension. Among these variants T2238C polymorphism in atrial natriuretic peptide gene has been investigated in the pathogeneses of hypertension, but studies have often generated controversial results. The aim of this study was to investigate the association between hypertension and the ANP/ T2238C variant gene that led to the loss of ScaI restriction site, thus eliminated the regular stop codon and involved an extension of the human ANP by two additional arginines. We genotyped 384 patients with hypertension and 435 healthy controls. The ScaI ANP gene polymorphism was determined by polymerase chain reaction-restriction fragment length polymorphism analysis. The results shows that the ScaI ANP gene polymorphism genotypes distribution and allele frequencies were not significantly different between the hypertensive and normotensive subjects (p>0.05). The frequencies of A2 wild allele and A1 mutant allele were 48% and 52% respectively in hypertensive patients and 49% and 51% in control group (p=0.66). This polymorphism is not associated with hypertension (OR= 1.55, 95% CI [0.82-2.92]; p=0.17) for TC and (OR=1.80, 95% CI [0.81-3.98]; p=0.14) for CC after adjustment for age, gender, body mass index, fasting glucose concentration, dyslipidemia and smoking. Furthermore, no relationship was found between clinical characteristics and ScaI ANP genotypes. As a conclusion; this study suggested that the ScaI ANP gene polymorphism is not associated with hypertension in the Tunisian population.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results